Envista Holdings Co. (NYSE:NVST – Free Report) – Equities researchers at Leerink Partnrs increased their FY2025 earnings estimates for Envista in a research report issued to clients and investors on Thursday, October 31st. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings of $1.07 per share for the year, up from their prior forecast of $0.97. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Envista’s current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for Envista’s FY2027 earnings at $1.41 EPS.
Envista (NYSE:NVST – Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.03. The business had revenue of $601.00 million during the quarter, compared to analyst estimates of $590.34 million. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The company’s revenue was down 4.8% on a year-over-year basis. During the same period last year, the firm posted $0.43 EPS.
View Our Latest Stock Report on Envista
Envista Price Performance
NVST stock opened at $21.28 on Monday. Envista has a 52 week low of $15.15 and a 52 week high of $25.64. The firm has a market capitalization of $3.66 billion, a P/E ratio of -2.74 and a beta of 1.30. The company has a fifty day simple moving average of $18.70 and a two-hundred day simple moving average of $18.06. The company has a quick ratio of 1.90, a current ratio of 2.08 and a debt-to-equity ratio of 0.42.
Institutional Investors Weigh In On Envista
Several hedge funds have recently made changes to their positions in NVST. Tweedy Browne Co LLC purchased a new position in Envista in the first quarter valued at about $21,053,000. SG Americas Securities LLC boosted its stake in Envista by 3,271.2% during the 1st quarter. SG Americas Securities LLC now owns 144,522 shares of the company’s stock valued at $3,090,000 after acquiring an additional 140,235 shares during the last quarter. M&G Plc grew its holdings in Envista by 12.5% during the 2nd quarter. M&G Plc now owns 306,253 shares of the company’s stock worth $5,206,000 after acquiring an additional 33,923 shares in the last quarter. Duality Advisers LP bought a new stake in shares of Envista in the 1st quarter worth about $1,903,000. Finally, Harbor Capital Advisors Inc. raised its stake in shares of Envista by 287.4% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 169,648 shares of the company’s stock valued at $2,821,000 after purchasing an additional 125,861 shares in the last quarter.
Insiders Place Their Bets
In related news, CFO Eric D. Hammes bought 24,532 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were bought at an average cost of $16.33 per share, for a total transaction of $400,607.56. Following the transaction, the chief financial officer now owns 24,532 shares of the company’s stock, valued at approximately $400,607.56. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 1.30% of the stock is currently owned by insiders.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
See Also
- Five stocks we like better than Envista
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Intel: Is Now the Time to Be Brave?Â
- Overbought Stocks Explained: Should You Trade Them?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Election Stocks: How Elections Affect the Stock Market
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.